Ovid Therapeutics (OVID)
(Real Time Quote from BATS)
$1.13 USD
-0.01 (-0.88%)
Updated Sep 25, 2024 01:16 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Ovid Therapeutics (OVID) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$3.24 | $5.00 | $1.20 | 184.21% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Ovid Therapeutics comes to $3.24. The forecasts range from a low of $1.20 to a high of $5.00. The average price target represents an increase of 184.21% from the last closing price of $1.14.
Analyst Price Targets (5 )
Broker Rating
Ovid Therapeutics currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, six are Strong Buy, representing 75% of all recommendations. A month ago, Strong Buy represented 75%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.44 | 1.44 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/30/2024 | William Blair | Sarah Schram | Not Available | Strong Buy |
8/19/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
8/15/2024 | Cowen & Co. | Ritu S Baral | Strong Buy | Strong Buy |
8/14/2024 | Wedbush Securities | Laura Chico | Strong Buy | Strong Buy |
8/13/2024 | B. Riley Securities | Kalpit Patel | Strong Buy | Strong Buy |
6/18/2024 | Not Identified | Not Identified | Strong Buy | Hold |
6/18/2024 | Not Identified | Not Identified | Hold | Hold |
6/18/2024 | BTIG | Thomas Shrader | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 8 |
Average Target Price | $3.24 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 82 of 253 |
Current Quarter EPS Est: | -0.19 |
OVID FAQs
Ovid Therapeutics (OVID) currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 8 brokerage firms.
The average price target for Ovid Therapeutics (OVID) is $3.24. The current on short-term price targets is based on 6 reports.
The forecasts for Ovid Therapeutics (OVID) range from a low of $1.2 to a high of $5. The average price target represents a increase of $184.21 from the last closing price of $1.14.
The current UPSIDE for Ovid Therapeutics (OVID) is 184.21%
Based on short-term price targets offered by five analysts, the average price target for Ovid Therapeutics comes to $3.24. The forecasts range from a low of $1.20 to a high of $5.00. The average price target represents an increase of 184.21% from the last closing price of $1.14.